ATRA
Atara Biotherapeutics Inc
9.40$
-3.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -99.0% | +9.0% | +38.8% | +40.6% | -3.1% | +605.2% | -91.4% | -95.0% | +454.8% | -21.9% | +123.4% | +98.9% | +543.4% | +4.7% | +40.3% | -18.5% | +199.7% | -82.1% | -80.4% | -53.8% | -67.6% | +22.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +6.8% | -2.7% | -95.8% | +2,428.0% | +6.9% | +2.7% | +12.5% | -5.3% | -13.4% | -93.6% | +1,348.2% | -99.6% | +1,240.3% | -9.7% | +20.8% | -37.2% | +133.1% | +64.3% | -10.6% | +200.8% | -97.3% | -79.2% | -9.6% | +19.2% | +54.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,433.1% | – | – | -91.4% | -1,440.0% | – | -291.9% | – | – | +2,223.4% | -5.4% | +35.7% | -20.3% | +199.4% | -78.1% | -80.4% | -55.3% | -73.7% | +12.0% | – | |
| – | -28.3% | +30.2% | +4.3% | +12.6% | +20.3% | +14.9% | +17.3% | +29.9% | +43.6% | -21.8% | +7.4% | +2.5% | +15.1% | -6.5% | +6.8% | -2.7% | +9.5% | -2.3% | +6.9% | +2.7% | +12.5% | -5.3% | -13.4% | +8.1% | -10.9% | -0.6% | -9.7% | +1.3% | -22.7% | +3.5% | -26.8% | +31.8% | -34.6% | -4.5% | -73.4% | -60.0% | -92.4% | -26.5% | +720.1% | – | |
| – | -26.1% | +63.3% | +11.5% | +15.1% | -0.3% | +26.8% | +37.5% | -12.3% | +16.0% | -1.7% | +21.1% | -18.3% | -5.0% | -5.7% | -3.8% | -9.5% | +8.9% | +9.9% | +9.4% | +2.3% | +9.9% | -5.7% | -8.5% | +0.6% | -48.1% | +41.2% | -3.9% | -8.2% | -6.5% | -3.0% | -19.8% | +16.9% | -9.4% | +21.6% | -48.3% | -32.8% | +7.3% | -15.9% | +6.0% | – | |
| – | -27.7% | +39.5% | +6.7% | +13.4% | +13.1% | +18.6% | +24.0% | +14.4% | +35.9% | -17.0% | +11.3% | -3.9% | +9.8% | -78.6% | -3.8% | -9.5% | +433.8% | -77.6% | +9.4% | +364.9% | -75.8% | -5.7% | +306.9% | +6.4% | -82.3% | +381.5% | -8.6% | -0.5% | -21.4% | +4.1% | -25.4% | +28.6% | -29.8% | +2.0% | -64.5% | -50.0% | -41.3% | -7.2% | +37.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -91.8% | -211.8% | – | – | – | – | |
| – | – | – | – | +0.0% | +100.0% | -36.0% | +0.0% | +0.0% | +0.0% | -10.2% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | – | – | – | -99.8% | +3,125.0% | -4.7% | +687.8% | +37.9% | +3.1% | +1.2% | -15.7% | -2.0% | +9.5% | -6.3% | -14.0% | +0.0% | -4.4% | -6.5% | -1.7% | -7.2% | -77.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -555.3% | – | – | – | – | – | – | – | – | – | – | -93.7% | -278.9% | – | – | – | – | |
| – | -2,571.4% | – | -200.0% | – | – | – | – | -200.0% | – | – | – | – | – | – | – | +500.0% | +33.3% | -4,762.5% | – | -3,481.3% | – | -483.3% | – | – | -80.0% | +1,000.0% | -95.5% | -2,000.0% | – | +118.2% | +714,237.5% | -100.0% | – | – | – | +833.3% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -555.4% | – | – | – | – | – | – | – | – | – | – | -93.7% | -280.3% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -512.3% | – | – | – | – | – | – | – | – | – | – | -91.2% | -192.6% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.